TELA Bio, Inc. (TELA)

Market Cap	161.70M
Revenue (ttm)	38.17M
Net Income (ttm)	-42.94M
Shares Out	16.76M
EPS (ttm)	-2.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,567
Open	8.37
Previous Close	8.44
Day's Range	8.14 - 8.62
52-Week Range	5.15 - 13.7
Beta	1.26
Analysts	Buy
Price Target	17.75 (+111.8%)
Earnings Date	Nov 9, 2022

About TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforc...

• Industry: Health Care Equipment & Supplies
• IPO Date: Nov 8, 2019
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: TELA

Full Company Profile

Financial Performance

In 2021, TELA Bio's revenue was $29.46 million, an increase of 61.77% compared to the previous year's $18.21 million. Losses were -$33.28 million, 15.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for TELA stock is "Buy." The 12-month stock price forecast is 17.75, which is an increase of 111.81% from the latest price.

Price Target

$17.75

(111.81% upside)

Analyst Consensus: Buy

Stock Forecasts